



SHL/SEC/2021

July 21, 2021

The Bombay Stock Exchange Limited  
Listing Department,  
1<sup>st</sup> Floor, New Trading Ring,  
Rotunda Building,  
Phiroze Jeejeebhoy Towers, Dalal Street, Fort  
Mumbai – 400 001.

The Calcutta Stock Exchange Ltd.  
7, Lyons Range  
Kolkata - 700 001 India

Company Code: 537253

Dear Sir,

Sub. : Outcome of the 245<sup>th</sup> Board Meeting held on 21.07.2021.

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Wednesday, July 21, 2021, the meeting was started at 03:30p.m., and concluded at 5:20 p.m.

1. **Approved Unaudited Financial Results (Standalone & consolidated) for the First quarter/three months ended June30, 2021 of the Financial Year 2021-22 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).**
2. Approved appointment of M/s. Link Intime India Private Limited, New Delhi an agency to conduct Remote e-voting/e-voting and Video conferencing for ensuing the 47<sup>th</sup> Annual General Meeting to be held on Tuesday, September 28, 2021.
3. Approved appointment of Mr. Tara Chand Sharma (FCS-5749 and C.P. No. 4078) Proprietor of M/s. Jain Sharma & Associate, Company Secretaries, Jaipur as Scrutinizer for conducting e-voting for the 47<sup>th</sup> Annual General Meeting.
4. Fixed Book Closure period from 21.09.2021 to 28.09.2021 for the purpose of ensuing Annual General Meeting to be held on Tuesday 28.09-2021 at registered office of the Company, New Delhi.
5. Fixed the date of ensuing Annual General Meeting to be held on Tuesday, 28.09.2021 at Registered office at **38E/252A, Vijay Tower, 3rd Floor, Panchsheel Commercial Complex, Shahpur Jat, New Delhi-110049** through **video conferencing/other Audio Visual Method** and approved the Cut-off date for determining the entitlements of Members to attend and vote at AGM will be September 21, 2021 and for sending of notice 13.08.2021.



**Sunil Healthcare Limited**

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662

You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,  
for **Sunil Healthcare Limited**

*SSK*  
*Sharma*

*21/07/2021*

**Santosh Kumar Sharma**  
**Company Secretary**

FCS-6817

Date: 21.07.2021

Place: New Delhi

Encl.: a/a



**STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2021**

Rs. in Lakhs

Particulars	Standalone			Year Ended		Consolidated			Year Ended	
	Quarter ended			Standalone		Quarter ended			Consolidated	
	30th June 2021	31st March 2021	30th June 2020	31st March 2021	30th June 2021	31st March 2021	30th June 2020	31st March 2021	30th June 2021	31st March 2021
	Unaudited	Audited (Refer note. 2)	Unaudited	Audited	Unaudited	Audited (Refer note. 2)	Unaudited	Audited	Unaudited	Audited
1 Revenue from Operations	2,617.99	2,264.88	2,100.18	8,963.11	2,650.78	2,329.77	2,163.40	9,029.19		
2 Other Income	18.59	128.48	14.44	562.07	24.41	115.24	13.02	554.33		
3 <b>Total Income (1+2)</b>	<b>2,636.58</b>	<b>2,393.36</b>	<b>2,114.62</b>	<b>9,525.18</b>	<b>2,675.19</b>	<b>2,445.01</b>	<b>2,176.42</b>	<b>9,583.52</b>		
4 <b>Expenses</b>										
a) Cost of Materials consumed	1,002.14	987.65	649.54	3,261.55	1,002.14	987.65	649.54	3,261.55		
b) Purchase of Stock-in-trade	-	(0.48)	-	-	-	(0.48)	-	-		
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	153.60	(16.23)	337.70	1,011.86	161.57	33.68	351.64	1,008.73		
d) Employees benefit expenses	349.73	291.87	308.88	1,229.52	349.73	291.87	308.88	1,229.52		
e) Finance Costs	106.46	137.64	146.57	530.85	106.46	137.64	146.57	530.85		
f) Depreciation and amortisation	155.34	150.71	151.64	611.30	155.38	150.72	151.65	611.35		
g) Other Expenses	832.22	827.00	518.65	2,845.16	868.10	894.44	586.04	2,996.84		
<b>Total Expenses</b>	<b>2,599.49</b>	<b>2,378.16</b>	<b>2,112.98</b>	<b>9,490.24</b>	<b>2,643.38</b>	<b>2,495.52</b>	<b>2,194.32</b>	<b>9,638.84</b>		
5 <b>Profit before tax from Continuing Operation(3-4)</b>	<b>37.09</b>	<b>15.20</b>	<b>1.64</b>	<b>34.94</b>	<b>31.81</b>	<b>(50.51)</b>	<b>(17.90)</b>	<b>(55.32)</b>		
6 <b>Tax Expenses (Net)</b>	<b>9.59</b>	<b>8.33</b>	<b>1.58</b>	<b>7.41</b>	<b>10.97</b>	<b>9.25</b>	<b>2.07</b>	<b>8.47</b>		
a) Current Tax										
i)-Current Tax	33.35	-	-	-	34.00	0.09	0.49	0.23		
ii)-Tax for Earlier Period	-	-	-	4.64	0.73	0.83	-	5.47		
b) Deferred Tax Charged/(Credit)	(23.76)	8.33	1.58	2.77	(23.76)	8.33	1.58	2.77		
7 <b>Profit/(loss) after tax from Continuing Operation</b>	<b>27.50</b>	<b>6.87</b>	<b>0.06</b>	<b>27.53</b>	<b>20.84</b>	<b>(59.76)</b>	<b>(19.97)</b>	<b>(63.79)</b>		
8 <b>Profit /(Loss) before tax from Discontinued Operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>		
Tax expenses from Discontinued Operations	-	-	-	-	-	-	-	-		
<b>Profit/(Loss) after tax from Discontinued Operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>		
<b>Profit/(Loss) after tax</b>	<b>27.50</b>	<b>6.87</b>	<b>0.06</b>	<b>27.53</b>	<b>20.84</b>	<b>(59.76)</b>	<b>(19.97)</b>	<b>(63.79)</b>		
9 <b>Other Comprehensive Income (OCI)</b>										
a) Items that will not be reclassified to Profit or Loss (net of tax)	-	1.98	-	1.98	-	1.98	-	1.98		
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	(6.24)	18.41	(1.71)	(26.27)		
10 <b>Total Comprehensive Income</b>	<b>27.50</b>	<b>8.85</b>	<b>0.06</b>	<b>29.51</b>	<b>14.60</b>	<b>(39.37)</b>	<b>(21.68)</b>	<b>(88.08)</b>		
11 Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48		
12 Other Equity				3,781.78				3,346.25		
13 Earning per share of Rs.10/- each(not annualised)(Continuing Operation)										
(a) Basic (Rs.)	0.27	0.07	0.00	0.27	0.20	(0.58)	(0.19)	(0.62)		
(b) Diluted (Rs.)	0.27	0.07	0.00	0.27	0.20	(0.58)	(0.19)	(0.62)		
Earning per share of Rs.10/- each(not annualised)(Discontinued Operation)										
(a) Basic (Rs.)	-	-	-	-	-	-	-	-		
(b) Diluted (Rs.)	-	-	-	-	-	-	-	-		
Earning per share of Rs. 10/- each(not annualised)										
(a) Basic (Rs.)	0.27	0.07	0.00	0.27	0.20	(0.58)	(0.19)	(0.62)		
(b) Diluted (Rs.)	0.27	0.07	0.00	0.27	0.20	(0.58)	(0.19)	(0.62)		

- COVID - 19 pandemic has caused serious disruption on the global economic and business environment. There is a huge uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these Financial results on the carrying value of its assets and liabilities as on 30.06.2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of these assets and to discharge its obligation adequate liquidity is available. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.
- The figures for the quarter ended March 31, 2021 are the balance figures between audited figures for the full financial and published year to date figures up to the third quarter of the previous financial year.
- The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.
- The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on July 21, 2021.

**Anil Khaitan**  
(Chairman cum Managing Director)  
DIN 00759951

# **JKVS & CO.**

## **Chartered Accountants**

**Review Report on unaudited standalone quarterly financial results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended**

**To the Board of Directors of Sunil Healthcare Limited**

We have reviewed the accompanying statement of unaudited standalone financial results ("Statement") of Sunil Healthcare Limited ("the Company") for the quarter ended June 30, 2021. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: New Delhi  
Date: July 21, 2021



For JKVS & Co.  
Chartered Accountants  
Firm Registration No. 318086E

  
Sajal Goyal  
Partner

Membership No. 523903  
UDIN: 21523903AAAADC3934



# **JKVS & CO.**

## **Chartered Accountants**

### **Independent Auditor's Review Report on consolidated unaudited quarterly financial results of Sunil Healthcare Limited, Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended**

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Sunil Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2021, ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities
  - a. Sunil Healthcare Mexico SA De CV (Incorporated in Mexico)
  - b. Sunil Healthcare North America LLC (Incorporated in USA)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# JKVS & CO.

6. The consolidated unaudited financial results include the interim financial results of two foreign subsidiaries whose financial statements are not required to review/audit according to the law of respective countries and whose financial results reflect total revenue from operation of Rs.86.75 Lakhs for the quarter ended June 30, 2021, and profit after tax of Rs. 0.45 Lakhs for the quarter ended June 31, 2021 and total comprehensive income of Rs. (6.24) Lakhs for the quarter ended June 31, 2021, as considered in the Statement. According to the information and explanations given to us by the management, these Interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

Place: New Delhi  
Date: July 21, 2021



For JKVS & Co.  
Chartered Accountants  
Firm Registration No. 318086E

Sajal Goyal  
Partner  
Membership No. 523903  
UDIN: 21523903AAAADC3934